Nav: Home

Researchers further illuminate pathway for treatment of cystic fibrosis

January 12, 2016

January 12, 2016 CHAPEL HILL, NC - It is well established that people with cystic fibrosis (CF) have two faulty copies of the CFTR gene, but debate continues on the question of whether certain symptoms of the airway disease are caused by the mutation or if the genetic defect precedes, but does not directly lead to some of the worst symptoms patients face.

Carla Ribeiro, PhD, associate professor of medicine, and her colleagues at the UNC Marsico Lung Institute/Cystic Fibrosis Research Center fall into the latter camp. A paper from this group, published in the American Journal of Critical Care Medicine, suggests new targets for therapy and further bolsters the case for inflammation as an acquired response unrelated to the CFTR genetic mutation.

"By studying alveolar macrophages, which provide our airways with a crucial defense against pathogens, we are able to more fully understand the larger picture of CF symptoms and continue progress towards targeted treatment for patients," Ribeiro said.

Alveolar macrophages are the body's first line of defense, and in healthy people these cells work to flush inhaled pathogens out of the airways. But, because in CF patients airway dehydration leads to mucus obstruction and persistent bacterial infection, the macrophages' heightened response to such pathogens causes a "snowball effect," resulting in hyper-inflammation, over-production of mucus, and chronic infection.

Ribeiro and colleagues Bob Lubamba, PhD, research specialist Lisa Jones, Wanda O'Neal, PhD, and Richard Boucher, MD, showed that CF alveolar macrophages are key contributors to the inflammation of CF airways, and that the overabundance of a protein called XBP-1 in these cells mediates their inflammatory effect. Ribeiro said she has focused much of her work in the past few years on trying to understand the role of this protein in CF airways disease.

To conduct the research, they harvested alveolar macrophages from human CF lungs and healthy lungs and showed that CF alveolar macrophages exhibit an increased basal inflammatory response when compared to healthy macrophages. When stimulated with factors present in CF airways, both sets of macrophages responded - but the inflammatory response of CF macrophages was larger. And, in both sets of cells, the inflammatory response was coupled to activation of XBP-1, but the activation was greater in CF macrophages.

They then over-expressed the activated XBP-1 protein in normal macrophages and reproduced the hyper-inflammatory phenotype found in CF macrophages. In contrast, decreasing the XBP-1 levels blunted the inflammatory response. These findings led the researchers to surmise that the XBP-1 pathway was implicated in the hyper-inflammatory response of CF alveolar macrophages. Because inhibition of CFTR function did not elicit a CF-like response in the macrophages harvested from healthy lungs, the research indicated that this particular immune response was not directly due to the CFTR mutation but was, instead, acquired.

"Our work has shown that the alveolar macrophage plays a key role in the pathogenesis of CF airway inflammation," Ribeiro said. "And that activation of XBP-1 mediates the secretion of inflammatory factors by alveolar macrophages. This is all helping to make a stronger case for why this pathway may be an important target for therapy."

Ribeiro added that this work could have implications in airway diseases beyond CF, including COPD and asthma.

In an editorial published along with the article, the potential therapeutic impact was forecast:

"Interventions aimed at XBP-1 or other molecules associated with sustaining the proinflammatory phenotype in the CF lung, in combination with antimicrobials and CFTR modulators, may provide improved resolution of infection and inflammation."
-end-
This research was supported by the National Institutes of Health, the Cystic Fibrosis Foundation, and a Scholarship for Excellence grant from Wallonia-Brussels International.

University of North Carolina Health Care

Related Cystic Fibrosis Articles:

Cystic fibrosis alters the structure of mucus in airways
Cystic fibrosis (CF) alters the structure of mucus produced in airway passages.
Cystic fibrosis study offers new understanding of silent changes in genes
Researchers studying the root cause of cystic fibrosis have made a major advance in our understanding of silent gene changes with implications for the complexity of cystic fibrosis.
New imaging technique shows effectiveness of cystic fibrosis drug
Cystic fibrosis currently has no cure, though a drug approved by the Food and Drug Administration treats the underlying cause of the disease.
New study resolves the structure of the human protein that causes cystic fibrosis
In order to better understand how genetic mutations give rise to cystic fibrosis, researchers need to map the protein responsible for the disorder.
New molecules identified that could help in the fight to prevent cystic fibrosis
New research has identified new molecules that could help in the fight to prevent diseases caused by faulty ion channels, such as cystic fibrosis.
Newborn screening for cystic fibrosis
A new study led by a team from the Research Institute of the McGill University Health Centre and Cystic Fibrosis Canada reinforces the benefits of newborn screening for cystic fibrosis (CF) patients.
Evolving insights into cystic fibrosis lung infections
Recent research progress into how bacteria adapt and evolve during chronic lung infections in cystic fibrosis patients could lead to better treatment strategies being developed, according to a new review by the University of Liverpool.
Key hurdle overcome in the development of a drug against cystic fibrosis
In people suffering from cystic fibrosis the CFTR protein is not located in the right place in mucus-producing cells: it remains inside the cell while it should be in the cell wall.
Researchers further illuminate pathway for treatment of cystic fibrosis
By studying alveolar macrophages, which provide our airways with a crucial defense against pathogens, UNC scientists are now able to more fully understand the larger picture of CF symptoms and continue progress towards targeted treatments, aside from addressing the mutated CFTR gene.
Gene therapy: A promising candidate for cystic fibrosis treatment
An improved gene therapy treatment can cure mice with cystic fibrosis (CF).

Related Cystic Fibrosis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#520 A Closer Look at Objectivism
This week we broach the topic of Objectivism. We'll be speaking with Keith Lockitch, senior fellow at the Ayn Rand Institute, about the philosophy of Objectivism as it's taught through Ayn Rand's writings. Then we'll speak with Denise Cummins, cognitive scientist, author and fellow at the Association for Psychological Science, about the impact of Objectivist ideology on society. Related links: This is what happens when you take Ayn Rand seriously Another Critic Who Doesn’t Care What Rand Thought or Why She Thought It, Only That She’s Wrong Quote is from "A Companion to Ayn Rand"